LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Biosensor System Developed for Blood Glucose Monitoring

By LabMedica International staff writers
Posted on 11 Jan 2018
Print article
Image: The skin-like biosensor system developed for noninvasive blood glucose monitoring (Photo courtesy of Tsinghua University).
Image: The skin-like biosensor system developed for noninvasive blood glucose monitoring (Photo courtesy of Tsinghua University).
Currently, noninvasive glucose monitoring is not widely appreciated because of its uncertain measurement, accuracy, weak blood glucose correlation and inability to detect hyperglycemia/hypoglycemia during sleep.

Regulated and continuous glucose monitoring (CGM) of diabetes patients can provide better monitoring and control of blood glucose and prevent complications and glucose monitoring with commercially available products relies on invasive lancet approaches.

Scientists at the Tsinghua University (Beijing, China) fabricated a skin-like biosensor system for noninvasive, in situ, and highly accurate intravascular blood glucose monitoring. The system integrates an ultrathin skin-like biosensor with paper battery–powered electrochemical twin channels (ETCs). The designed subcutaneous ETCs drive intravascular blood glucose out of the vessel and transport it to the skin surface.

The ultrathin (~3 μm) nanostructured biosensor, with high sensitivity (130.4 μA/mM), fully absorbs and measures the glucose, owing to its extreme conformability. The ultrathin skin-like biosensors completely conform to the skin and measure the outward-transported glucose driven by ETCs. These biosensors are multilayered with “sand dune” nanostructures, which exhibit better electrochemical properties and higher sensitivity.

The team conducted in vivo human clinical trials. Invasive glucose measurement was done using a commercial glucometer and vein-detained needles. The skin-like noninvasive blood glucose monitoring system measured the intravascular blood glucose and the glucose in interstitial fluid (ISF). The ETCs greatly improve the correlation between the noninvasive measurement results and the real blood glucose level. With proper calibration, the system is potentially suitable for medical-grade CGM and insulin therapy when working with micro-insulin pumps. The study was published on December 1, 2017, in the journal Science Advances.

Related Links:
Tsinghua University

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article

Channels

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more